D.E. Shaw & Co
TBPH icon

D.E. Shaw & Co’s Theravance Biopharma TBPH Stock Holding History

D.E. Shaw & Co’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-16,800
Closed -$251K – 3998
2014
Q4 		$251K Hold
16,800
– – ﹤0.01% 3718
2014
Q3 		$387K Buy
+16,800
New +$487K ﹤0.01% 3537

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's TBPH Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Theravance Biopharma (TBPH) stake by 24% in Q1 2026, selling an estimated $5.41M and leaving 954,042 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1316.

D.E. Shaw & Co first reported a position in TBPH in Q2 2014 and has held it in 45 quarters since. The position peaked at $23.6M in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • D.E. Shaw & Co held 954,042 shares of Theravance Biopharma worth $15.5M as of Q1 2026.
  • D.E. Shaw & Co sold 305,899 Theravance Biopharma shares in Q1 2026, an estimated $5.41M.
  • Theravance Biopharma made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1316 holding.
  • D.E. Shaw & Co first reported a position in Theravance Biopharma in Q2 2014 and has held it in 45 quarters since.
  • D.E. Shaw & Co's Theravance Biopharma position peaked at $23.6M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.